IP Library › Granted Patent US 12,397,025
Granted Patent B2
US 12,397,025 · App. 17/655,825 · Granted Aug 26, 2025

Method for facilitating maturation of the mammalian immune system

Inventors: David Kyle (Davis, CA); Steven Frese (Oakland, CA); Samara Freeman-Sharkey (Davis, CA); Bethany Henrick (Davis, CA)
Assignee: INFINANT HEALTH, INC
A61K35/747A23K10/18A23L33/135A23L33/40A61K31/702A61K35/741A61K35/744A61K35/745C12Q1/689A23V2002/00A23V2400/529A23V2400/533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,025
App. No.
17/655,825
Granted
Aug 26, 2025
Kind
B2
Abstract

The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.

Claims (24)

1. A method of controlling the intestinal environment of a mammal by increasing and/or maintaining a level of short chain fatty acids (SCFA) or organic acids in the mammal's colon, the method comprising:

a) selecting a dysbiotic mammal having a lactate:acetate ratio of less than 2:3 in its feces; and

b) administering to the mammal a bacterial composition comprising bacteria capable of colonization of the mammal's colon; and

c) adding one or more mammalian milk oligosaccharides (MMO) to the mammal's diet as necessary to maintain MMO as at least 10% of total dietary fiber in the mammal's diet.

2. The method of claim 1 , wherein the method reduces antibiotic resistance gene load of at least one gene in the mammal's colon, wherein the antibiotic resistance gene load of said at least one gene is reduced by greater than 25%, 50%, 75%, 80%, or 85%, and/or wherein pathogenic bacteria in the feces is reduced by 20%, and/or wherein the firmness of stool composition of the mammal is increased.

3. The method of claim 1 , wherein the bacterial composition is provided to the mammal contemporaneously or within 2 hours of the addition of the MMO.

4. The method of claim 1 , wherein the bacterial composition and/or MMO are administered daily or for a period of at least 2, at least 5, at least 10, at least 20, at least 30, at least 60, at least 90, at least 120, at least 150, or at least 180 days.

5. The method of claim 1 , wherein the mammal is receiving MMO at a dose representing over 25%, over 40%, or over 50% of the total dietary fiber.

6. The method of claim 1 , wherein the MMO consists of carbohydrate polymers found in mammalian milk which are not metabolized by any combination of digestive enzymes expressed from mammalian genes.

7. The method of claim 1 , wherein the MMO is added in a food composition.

8. The method of claim 7 , wherein the food composition comprises mammalian milk, mammalian milk derived product, and/or mammalian donor milk.

9. The method of claim 7 , wherein the food composition comprises infant formula, a milk replacer, an enteral nutrition product, and/or meal replacer for the mammal, or wherein the food composition is sufficient to sustain growth of the mammal.

10. The method of claim 1 , wherein the bacterial composition comprises bacteria that can grow in an anaerobic culture whose sole carbon source is MMO.

11. The method of claim 1 , wherein at least one species of the bacterial composition comprises bacteria capable of expressing genes for a transporter that internalizes one or more MMOs intact.

12. The method of claim 1 , wherein the bacterial composition comprises bacteria of a genus selected from the group consisting of Bifidobacteria, Lactobacillus and Pediococcus.

13. The method of claim 1 , wherein the bacteria are B. adolescentis, B. animalis, B. animalis subsp. animalis, B. animalis subsp. lactis, B. bifidum, B. breve, B. catenulatum, B. longum, B. longum subsp. infantis, B. longum subsp. longum, B. pseudocatanulatum, B. pseudolongum, L. acidophilus, L. antri, L. brevis, L. casei, L. coleohominis, L. crispatus, L. curvatus, L. fermentum, L. gasseri, L. johnsonii, L. mucosae, L. pentosus, L. plantarum, L. reuteri, L. rhamnosus, L. sakei, L. salivarius, P. acidilactici, P. argentinicus, P. claussenli, P. pentosaceus, P. stilesii L. paracasei, L. kisonensis, L. paralimentarius, L. perolens, L. apis, L. ghanensis, L. dextrinicus, L. shenzenensis, L. harbinensis, P. parvulus , or P. lolii.

14. The method of claim 1 , wherein the mammal is a pre-term infant or a term infant.

15. The method of claim 1 , wherein the mammal is an infant born by C-section.

16. The method of claim 1 , wherein the mammal is a dysbiotic infant.

17. The method of claim 1 , wherein the mammal is a dysbiotic infant having a stool pH of 5.5 or above, 6.0 or above, or 6.5 or above.

18. The method of claim 1 , wherein the bacterial composition is administered for a period and in an amount sufficient to maintain bacterial species capable of consuming MMO by internalization of that MMO within bacterial cell at a level of at least 10 6 cfu/g feces, preferably 10 8 cfu/g feces.

19. The method of claim 1 , wherein the MMO is administered to said mammal prior to the administration of the bacterial composition, or

wherein the MMO is administered to said mammal after the administration of the bacterial composition, or

wherein the MMO is administered to said mammal contemporaneously with the administration of the bacterial composition.

Assignments (2)
CHANGE OF NAME Recorded Nov 10, 2022
From: EVOLVE BIOSYSTEMS INC.
To: INFINANT HEALTH, INC
Reel/Frame 061914/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2022
From: KYLE, DAVID; FRESE, STEVEN; FREEMAN-SHARKEY, SAMARA; HENRICK, BETHANY
To: EVOLVE BIOSYSTEMS, INC.
Reel/Frame 059337/0895 →
Continuity (4)
Continuation 16314580
Provisional Application 62397788 · Sep 21, 2016
Provisional Application 62357820 · Jul 1, 2016
Related Publication 20220313759A1 · Oct 6, 2022
References Cited (41)
US 20100303837A1 · Goletz et al. · 2010 [cited by applicant]
US 20110066700A1 · Chao · 2011 [cited by applicant]
US 20120172319A1 · Chow et al. · 2012 [cited by applicant]
US 20140037785A1 · Barboza et al. · 2014 [cited by applicant]
US 20150265661A1 · Newburg et al. · 2015 [cited by applicant]
US 20160120915A1 · Blaser et al. · 2016 [cited by applicant]
CN 101272701A · 2008 [cited by applicant]
CN 103338775A · 2013 [cited by applicant]
CN 103402376A · 2013 [cited by applicant]
CN 103763940A · 2014 [cited by applicant]
CN 105166914A · 2015 [cited by applicant]
WO 2013154725A1 · 2013 [cited by applicant]
WO 2014121304A1 · 2014 [cited by applicant]
WO 2015095241A2 · 2015 [cited by applicant]
WO 2016065324A1 · 2016 [cited by applicant]
WO 2016066763A1 · 2016 [cited by applicant]
WO 2016094836A1 · 2016 [cited by applicant]
WO 2016105513A1 · 2016 [cited by applicant]
WO 2016141454A1 · 2016 [cited by applicant]
WO 2017053544A1 · 2017 [cited by applicant]
WO 2017084673A1 · 2017 [cited by applicant]
Sandra JM ten Bruggencate “Functional role and mechanisms of sialyllactose and other sialylated milk oligosaccharides” Nutrition Reviews, vol. 72, Issue 6, Jun. 1, 2014, pp. 377-389 (Year: 2014). [cited by examiner]
Underwood et al., “Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota.” Pediatric Research 78(6): 670-677 (2015). [cited by applicant]
Bekkali et al. “Infant stool form scale: development and results.” J Pediatr. 154(4): 521-526.e1 (2009). [cited by applicant]
Lozupone et al. “Diversity, stability and resilience of the human gut microbiota.” Nature 489(7415): 220-230 (2012). [cited by applicant]
Schwab et al. “Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides.” FEMS Microbiol Lett 315: 141-148 (2011). [cited by applicant]
Stecher et al. “‘Blooming’ in the gut: how dysbiosis might contribute to pathogen evolution.” Nat Rev Microbiol. 11(4): 277-284 (2013). [cited by applicant]
Underwood et al., “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut.” Pediatr Res 77(1-2): 229-235 (2015). [cited by applicant]
Weese et al., “Evaluation of Lactobacillus pentosus WE7 for prevention of diarrhea in neonatal foals.” JAVMA 226(12): 2031-2034 (2005). [cited by applicant]
Yassour et al. “Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability.” Science Translational Medicine 8(343): 343ra81 (2016). [cited by applicant]
MacFarlane et al., “Regulation of short-chain fatty acid production,” Proceedings of the Nutrition Society, vol. 62, 2003, pp. 67-72. [cited by applicant]
Kim et al., “Gut microbiota lipopolysaccharide accelerates inflamm-aging in mice,” BMC Microbiology, vol. 16, 2016, pp. 1-9. [cited by applicant]
Bezkorovainy, “Probiotics: determinants of survival and growth in the gut,” Am. J. Clin. Nutr., vol. 73, 2001, pp. 399S-405S. [cited by applicant]
Morinaga Probiotics Center, “B. Infantis M-63,” 2 pages, Accessed Feb. 27, 2021. [cited by applicant]
Bannister-Tyrrell et al., “Variation in hospital caesarean section rates for preterm births,” Australian and New Zealand Journal of Obstetrics and Gynaecology 2015; 55: 350-356. [cited by applicant]
Underwood, Mark A., et al. “A comparison of two probiotic strains of bifidobacteria in premature infants.” The Journal of pediatrics 163.6: 1585-1591 (2013). [cited by applicant]
Bin-Nun et al., “Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates.” The Journal of pediatrics 147.2: 192-196 (2005). [cited by applicant]
Hoyos, “Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit.” International Journal of In… [cited by applicant]
Judge Jorge L. Alonso. “Memorandum Opinion and Order” in [cited by applicant]
Lin et al. “Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.” Pediatrics 115(1): 1-4 (2005). [cited by applicant]
Interlocutory Decision in Opposition of EP Patent 3,209,308 (Jun. 6, 2025). [cited by applicant]